Other languages Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Real-time Estimate Cboe BZX Other stock markets 03:16:25 2024-04-25 pm EDT			5-day change	1st Jan Change
11.62 ^USD	-0.73%		-1.32%	+42.25%

Mar. 29	General (Ret.) Merrill A. McPeak, Member of the Board of Directors of Iovance Biotherapeutics, Inc. Retires and Not Stands for Re-Election	CI
Mar. 14	Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

General (Ret.) Merrill A. McPeak, Member of the Board of Directors of Iovance Biotherapeutics, Inc. Retires and Not Stands for Re-Election	Mar. 29
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday	Mar. 04
Iovance Biotherapeutics Says FDA Lifts Partial Clinical Hold on Lung Cancer Study	Mar. 04
Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer	Mar. 04
Iovance Biotherapeutics Q4 Loss Narrows, Posts Revenue	Feb. 29
Iovance Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28
Iovance Biotherapeutics Insider Bought Shares Worth $45,750,000, According to a Recent SEC Filing	Feb. 21
Iovance Biotherapeutics Insider Bought Shares Worth $292,800, According to a Recent SEC Filing	Feb. 21
Iovance Biotherapeutics Insider Bought Shares Worth $2,287,500, According to a Recent SEC Filing	Feb. 21
Sector Update: Health Care Stocks Lower Late Afternoon	Feb. 20
Sector Update: Health Care	Feb. 20
Top Midday Gainers	Feb. 20
Iovance Biotherapeutics Rises After Analyst Actions, Stock Offering	Feb. 20
Iovance Biotherapeutics Prices $211 Million Share Offering; Shares Surge	Feb. 20
Dwindling Rate Cut Hopes Push Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	Feb. 20
Top Premarket Gainers	Feb. 20
Iovance Biotherapeutics' Amtagvi for Advanced Melanoma Receives Accelerated FDA Approval	Feb. 16
US FDA grants accelerated approval for Iovance's skin cancer cell therapy	Feb. 16
FDA approves Iovance Biotherapeutics cell therapy for skin cancer	Feb. 16
Iovance Biotherapeutics, Inc.?s AMTAGVI? (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma	Feb. 16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Other languages

Filters